基于CT影像生物标志物的人工智能模型预测慢性乙型肝炎患者肝细胞癌
本研究利用深度学习CT自动分割提取的影像生物标志物联合临床变量,开发了梯度提升机模型PLAN-B-DF,用于预测慢性乙型肝炎患者的肝细胞癌风险。推导队列5585例按3:1分为训练集和内部验证集,外部验证队列2883例。外部验证中PLAN-B-DF的c-index为0.89,优于PLAN-B、PAGE-B等既往模型(0.65-0.78),并保持良好校准。
要点
- PLAN-B-DF整合6项CT影像生物标志物和8项临床变量预测慢性乙型肝炎患者肝细胞癌风险。
- 外部验证中PLAN-B-DF的c-index为0.89,优于既往模型(0.65-0.78,均p<0.001)。
- 按PLAN-B-DF风险概率分组,10年累积肝细胞癌发生率最低危组0.0%、低危组0.4%、中危组16.0%、高危组46.2%。
核心结论
- 该人工智能预测模型整合基于深度学习的CT图像自动分割,在预测慢性乙型肝炎患者肝细胞癌风险方面较既往模型表现更优。
研究设计与样本
- 采用梯度提升机算法开发人工智能预测模型,利用深度学习CT自动分割软件DeepFore提取影像生物标志物。
- 推导队列5585例随机按3:1分为训练集和内部验证集,外部验证队列2883例。
- 选取6项影像生物标志物和8项临床变量作为模型PLAN-B-DF的主要变量。
主要发现
- 内部验证集(中位随访7.4年)中PLAN-B-DF的c-index为0.91,校准良好(Hosmer-Lemeshow检验p=0.78)。
- 外部验证队列(中位随访4.6年)中PLAN-B-DF的c-index为0.89,优于PLAN-B、PAGE-B、改良PAGE-B和CU-HCC(c-index 0.65-0.78,均p<0.001),校准良好(Hosmer-Lemeshow检验p=0.42)。
- 按PLAN-B-DF风险概率分为四组,10年累积肝细胞癌发生率在最低危组为0.0%、低危组为0.4%、中危组为16.0%、高危组为46.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Various hepatocellular carcinoma (HCC) prediction models have been proposed for patients with chronic hepatitis B (CHB) using clinical variables. We aimed to develop an artificial intelligence (AI)-based HCC prediction model by incorporating imaging biomarkers derived from abdominal computed tomography (CT) images along with clinical variables. METHODS: An AI prediction model employing a gradient-boosting machine algorithm was developed utilizing imaging biomarkers extracted by DeepFore, a deep learning-based CT auto-segmentation software. The derivation cohort (n = 5,585) was randomly divided into the training and internal validation sets at a 3:1 ratio. The external validation cohort included 2,883 patients. Six imaging biomarkers (i.e. abdominal visceral fat-total fat volume ratio, total fat-trunk volume ratio, spleen volume, liver volume, liver-spleen Hounsfield unit ratio, and muscle Hounsfield unit) and eight clinical variables were selected as the main variables of our model, PLAN-B-DF. RESULTS: In the internal validation set (median follow-up duration = 7.4 years), PLAN-B-DF demonstrated an excellent predictive performance with a c-index of 0.91 and good calibration function (p = 0.78 by the Hosmer-Lemeshow test). In the external validation cohort (median follow-up duration = 4.6 years), PLAN-B-DF showed a significantly better discrimination function compared to previous models, including PLAN-B, PAGE-B, modified PAGE-B, and CU-HCC (c-index, 0.89 vs. 0.65-0.78; all p <0.001), and maintained a good calibration function (p = 0.42 by the Hosmer-Lemeshow test). When patients were classified into four groups according to the risk probability calculated by PLAN-B-DF, the 10-year cumulative HCC incidence was 0.0%, 0.4%, 16.0%, and 46.2% in the minimal-, low-, intermediate-, and high-risk groups, respectively. CONCLUSION: This AI prediction model, integrating deep learning-based auto-segmentation of CT images, offers improved performance in predicting HCC risk among patients with CHB compared to previous models. IMPACT AND IMPLICATIONS: The novel predictive model PLAN-B-DF, employing an automated computed tomography segmentation algorithm, significantly improves predictive accuracy and risk stratification for hepatocellular carcinoma in patients with chronic hepatitis B (CHB). Using a gradient-boosting algorithm and computed tomography metrics, such as visceral fat volume and myosteatosis, PLAN-B-DF outperforms previous models based solely on clinical and demographic data. This model not only shows a higher c-index compared to previous models, but also effectively classifies patients with CHB into different risk groups. This model uses machine learning to analyze the complex relationships among various risk factors contributing to hepatocellular carcinoma occurrence, thereby enabling more personalized surveillance for patients with CHB.
引用
- Shin H, Hur MH, Song BG, et al. AI model using CT-based imaging biomarkers to predict hepatocellular carcinoma in patients with chronic hepatitis B. J Hepatol. 2024. PMID: 39710148. doi:10.1016/j.jhep.2024.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。